References
- Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001; 128: 114–119
- Huntly B J, Reid A G, Bench A J, Campbell L J, Telford N, Shepherd P, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732–1738
- Pieńkowska-Grela B, Rygier J, Woroniecka R, Grygalewicz B, Pastwińska A, Krawczyk P, et al. Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib. Leuk Lymphoma 2009; 50: 952–965
- Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005; 105: 2281–2286
- Kim D H, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner H A, et al. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Cancer 2008; 113: 772–781
- Huntly B J, Guilhot F, Reid A G, Vassiliou G, Hennig E, Franke C, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102: 2205–2212
- Sinclair P B, Nacheva E P, Leversha M, Telford N, Chang J, Reid A, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738–743
- Storlazzi C T, Specchia G, Anelli L, Albano F, Pastore D, Zagaria A, et al. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 2002; 35: 271–276
- Huntly B J, Bench A, Green A R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003; 102: 1160–1168
- Chaubey A, Karanti S, Rai D, Oh T, Adhvaryu S G, Aguiar R C. MicroRNAs and deletion of the derivative chromosome 9 in chronic myeloid leukemia. Leukemia 2009; 23: 186–188
- Druker B J, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417